“…Alternative expression strategies have been developed by the fusion of AMPs with partner proteins that decrease product toxicity to host cells, enhance product stability, facilitate product recovery, and/or aid in the acquisition of biological activity of the AMP product (5,6,10,11,16,25,26,29,36,39). Previous studies have investigated AMPs fused with several partners, including bovine prochymosin (11), maltose-binding protein (10,25), F4 of the E. coli intracellular protein PurF (16,28), green fluorescent protein (GFP) (36), Pap3.30 from the Pseudomonas aeruginosa bacteriophage PaP3 (29), bacterial thioredoxin (2), RepA of E. coli (39), intein (21), L-ribulokinase of Salmonella enterica serovar Typhimurium (5), the Cterminal fragment of light meromyosin (6), glutathione S-transferase (26), and immunoglobulin G (IgG)-binding domains from protein A (26).…”